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Joanna Neuhoff-Murawska1 and Pawel Matusik5Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is a liver manifestation of metabolic syndrome since
obesity and insulin resistance are the main pathogenic contributors for both conditions. NAFLD carries
increased risk of atherosclerosis and cardiovascular diseases. There is an urgent need to find effective and
safe therapy for children and adults with NAFLD. Data from research and clinical studies suggest that
omega-3 fatty acids may be beneficial in metabolic syndrome-related conditions and can reduce the risk of
cardiovascular disease.
Methods/design: We are conducting a randomized, multicenter, double-blind, placebo-controlled trial of
treatment with omega-3 fatty acids in children with NAFLD. Patients are randomized to receive either
omega-3 fatty acids containing docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) or placebo for
24 weeks. The dose of omega-3 (DHA+ EPA) ranges from 450 to 1300 mg daily. Low calorie diet and
increased physical activity are advised and monitored using validated questionnaires. The primary outcome
of the trial is the number of patients who decreased ALT activity by ≥ 0,3 of upper limit of normal. The
main secondary outcomes are improvement in the laboratory liver tests, liver steatosis on ultrasound,
markers of insulin resistance and difference in fat/lean body mass composition after 6 months of
intervention.
Discussion: Potential efficacy of omega-3 fatty acids in the treatment of NAFLD will provide needed rationale for
use of this safe diet supplement together with weight reduction therapy in the growing population of children
with NAFLD.
Trial registration: Clinicaltrials.gov: NCT01547910
Keywords: Non-alcoholic fatty liver disease, Omega-3 fatty acids, Polyunsaturated fatty acids, Randomized
controlled trial, ChildrenBackground
Non-alcoholic fatty liver disease (NAFLD) comprises
spectrum of liver damage that ranges from simple
steatosis through steatohepatitis (NASH), fibrosis to
cirrhosis, end-stage liver disease and occasionally he-
patocellular carcinoma. Although the natural history
of NAFLD remains yet to be defined, it is now clear* Correspondence: w.janczyk@czd.pl
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Memorial Health Institute, Warsaw, Poland
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reproduction in any medium, provided the orthat NAFLD and especially NASH carries increased
risk of atherosclerosis, cardiovascular disease (CVD)
and overall mortality when compared to general popu-
lation [1-8]. Emerging evidence suggests that the main
cause of death in NAFLD is CVD what strongly reflects
its very close relation to metabolic syndrome (MS)
[1-3]. In patients who develop liver steatosis at younger
age the complications of the liver disease and metabolic
syndrome may appear sooner, therefore they require
special concern and early management.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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apy in NAFLD. Dietary restrictions are as important
as physical activity and changes in lifestyle [9-12]. However
compliance is poor in these patients and there is too much
inconsistent data from the clinical trials to indicate the op-
timal rate and extent of weight loss in children.
Pharmacological treatment remains unsuccessful in
both children and adults with NAFLD. In the plan-
ning phase of this trial we performed a systematic
review of literature on pharmacological interventions
for NAFLD [13]. Use of probucol, pioglitazone, met-
formin and carnitine in high doses may be promising
but in conclusion none of the pharmacological agents
could be recommended for treatment of NAFLD, es-
pecially in children. Recent two large clinical trials
using vitamin E and pioglitazone in NAFLD showed
conflicting results [14,15].
Omega-3 long-chain polyunsaturated fatty acids are
safe diet supplements that showed efficacy in the preven-
tion and therapy of cardiovascular diseases, dyslipidemia
and metabolic syndrome [16-19]. In a paucity of effective
treatment they may constitute safe pharmacological op-
tion for children with NAFLD.
Recently Parker et al. published systematic review and
meta-analysis of studies of omega-3 LC-PUFA (long-
chain polyunsaturated fatty acids) supplementation in
adults with NAFLD [20]. Nine studies (5 RCTs), involv-
ing 355 individuals were included. Patients were given ei-
ther omega-3 LC-PUFA or control treatment. Duration
of therapy ranged from 8 weeks to 12 months, as well
as the dose of LC-PUFA - from 0,25g to 13,7g per
day. In conclusion of the review, omega-3 fatty acids
were claimed beneficial vs. placebo in reducing liver
fat (estimated by liver biopsy, ultrasound or 1H-MRS)
(effect size = ˙0.97, 95% CI: ˙0.58 to ˙1.35, p <0.001)
and decreasing AST (effect size = ˙0.97, 95% CI: ˙0.13
to ˙1.82, p = 0.02) but not ALT activity. However the
current data are not sufficient to set the optimal dose of
LC-PUFA in NAFLD.N=38 Fish oil (DHA+EPA=3:2) 450-13
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Figure 1 Schematic of the trial design.So far there has been only one randomized controlled
trial that assessed efficacy of LC-PUFA in children with
NAFLD [21]. Patients were assigned to receive 250 mg
or 500 mg of DHA (docosahexaenoic acid) per day or
placebo for 6 months. Beneficial results of DHA were
expressed in the improvement of level triglycerides,
markers of insulin resistance and liver fat assessed by
ultrasound. DHA did not show significant effect on
ALT activity.
Below we describe design of our multicenter, random-
ized, double-blind, placebo-controlled trial of omega-3
LC-PUFA supplementation in children with NAFLD.
Methods
Study design overview
We are conducting a multi-center, randomized, placebo-
controlled, double-blind clinical trial to assess efficacy of
treatment with omega-3 LC-PUFA in children with
established NAFLD. Eligible patients are randomized to
two arms: these who receive either fish oil containing
omega-3 LC-PUFA: docosahexaenoic acid (DHA) and
eicosapentaenoic acid (EPA) (450 to 1300 mg daily), or
placebo (sunflower oil) for 24 weeks.
The main aim of the study is to determine whether
supplementation of omega-3 LC-PUFA improves bio-
chemical parameters of liver function, markers of insulin
resistance, serum lipid profile and liver steatosis on
ultrasound in patients with non-alcoholic fatty liver dis-
ease. Primary comparisons will be made using an
intention-to-treat analysis at week 12 and 24. Per proto-
col analysis will be also applied for the same time points.
The follow-up visit is planned after 6 months after dis-
continuation of study treatment. A schematic of the trial
design is shown on Figure 1.
Participant selection
Children aged 6 to 19 years old were recruited at the 4
Polish pediatric hospitals from July 2008 till April
2011 (the participating centers are listed in the00mg per day
00mg per day
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into the trial according to the screening procedures. All
participants and their parents gave written consent be-
fore enrollment. Ethical approval was obtained from
the Children’s Memorial Health Institute Bioethical
Committee, Warsaw, Poland. The CONSORT flowchart
is presented on Figure 2.
Inclusion criteria
Patients had to fulfill all of the following inclusion criteria:
– written consent of a patient (if at least 16 years old)
and parents,
– age: over 5 and below 19 years old,Ran
(
Allocated to omega-3 and treated
(n=38)





































Figure 2 Patient CONSORT flowchart.– overweight or obesity (BMI> 90pc according to
IOTF BMI charts),
– ALT activity ≥ 1,3 ULN (upper limit of normal),
– hyperechogenicity of the liver on ultrasound or liver
histology consistent with NAFLD/NASH (≥ 5% of
hepatocytes with macrovesicular fat)
Hyper-ALT and liver steatosis on ultrasound are the most
common diagnostic criteria for NAFLD used in the clinical
practice. However usually the grade of ALT elevation is not
defined. To increase sensitivity and specificity of diagnosis
of NAFLD we used combined criteria of 1,3 ULN of ALT









Withdrawn by parents/patient (n=6)




Not meeting inclusion criteria (n=9)
Declined to participate (n=1)
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[22,23].
Exclusion criteria
To be eligible to participate in the trial patients had to
undergo thorough screening of any other conditions that
might mimic the diagnosis of NAFLD or could interfere
with analysis of treatment efficacy. Exclusion criteria com-
prised of any pathologic conditions affecting liver as HBV,
HCV infection, chronic and acute liver failure, cholestasis,
metabolic diseases like α1-antitripsin deficiency, Wilson




 Age < 5 or > 19 years
 Current or history of significant alcohol
consumption
 Unlikely to co-operate in the study, to comply with
study treatment or with the study visits.
Medical and therapeutic criteria:
1. Concerning liver diseases: Past or active HBV infection
 Past or active HCV infection









 Any recognized liver disease presenting with
elevated ALT other than NAFLD/NASH
2. Concerning other concomitant diseases or
associated clinical conditions:
 History of diabetes mellitus
 Familiar hypercholesterolemia
 Hypothyroidism
 Current or history of craniopharyngioma
 Any medical condition that considered by
physician can unable completion of the trial
3. Concerning concomitant medications:
 Treatment with vitamin E, statins, UDCA,
probiotics or metformin within 3 months prior to
randomization
 Pharmacological treatment of hypertension
within 3 months prior to randomization
 History of parenteral nutrition
In accordance to the recent recommendations of
the European Society of Pediatric Gastroenterology,Hepatology and Nutrition (ESPGHAN) on NAFLD diag-
nostics [24], liver biopsy was proposed to the patients in
whom elevation of ALT lasted for over 6 months during
weight reduction therapy.
Treatment groups
Patients who were selected to participate in the study
and gave their written consent were randomly assigned
to one of the two therapeutic groups:
▪ Omega-3 group: 450-1300 mg omega-3 fatty acids
(containing DHA and EPA in 3:2 proportion) in two
doses per day, to be taken with morning and evening
meal. The dose of omega-3 was dependent on
patient’s weight (see Table 1).
▪ Placebo/comparator group: the same dose of
sunflower oil (containing omega-6 LC-PUFA).
Planned duration of the treatment is 24 weeks. Omega-3
and placebo are administered orally twice a day in the
same dose and formulation of brown-colored and oval-
shaped capsules. Capsules used in this study contain
omega-3 LC-PUFA which was originally obtained from the
marine algae. Study drugs were manufactured and blinded
by Hasco-Lek, PolandW from the composition of the fol-
lowing ingredients: Incromega DHA 500 TG SR, Croda,
PolandW (consisting of 100 mg/g EPA and 500 mg/g DHA)
and Incromega EPA 500 TG SR, Croda, PolandW
(consisting of 500 mg/g EPA and 100 mg/g DHA).
Throughout the whole treatment period (6 months)
and next 6 months of the follow-up patients are advised
to lose weight based on modification of their lifestyle
(low-calorie diet and physical exercise). Pharmacological
agents e.g. vitamin E, metformin, thiazolidinediones,
statins, UDCA, probiotics or any that may affect body
weight reduction, insulin resistance, lipid profile or fatty
liver are not allowed to use during the trial.
Dietary assessment
Simultaneously with pharmacological treatment, each
patient received individually tailored dietary recommen-
dations aimed to reduce body weight.
Detailed information about current quantity and qual-
ity of the patient’s diet was gathered by an experienced
dietician in every center. Dieticians analyzed intake of
total energy, essential nutrients as proteins, carbohy-
drates (including sucrose), fiber, lipids, main minerals,
lipid- and water-soluble vitamins, cholesterol, saturated
fatty acids, monounsaturated fatty acids and LC-PUFA
including α-linoleic acid (ALA), linolenic acid (LA), ara-
chidonic acid (ARA), DHA and EPA.
Various assessment methods including food records and
dietary recalls are subjected to considerable error and bias,
and none of these is considered as a 'gold standard' [25]. In
Table 1 Dosage of omega-3 fatty acids
Body weight [kg] Approx. total omega-3 daily dose [mg] DHA daily dose [mg] EPA daily dose [mg] Dosage scheme
Under 40 450 267 177,5 Twice a day
40-60 900 534 355 Twice a day
Over 60 1300 800 532,5 Twice a day
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their parents using 3-days record (3dr) and food frequency
questionnaire (FFQ). To assess portion size we used
Album of Photographs of Food Products and Dishes by
National Food and Nutrition Institute in both methods.
3-day food record
3-day food record is commonly used and well recog-
nized method of dietary assessment. It requires reporting
all the food and beverages consumed for three consecu-
tive days (2-week days and 1-weekend day).
All participants of the study had to complete 3-day
food record at week 0 (M0). They were previously
instructed by a dietician how to fill in the food records.
Patients were asked to specify the volume of consumed
food with usual household measurements (e.g. cups, ta-
blespoons) or to indicate the weight of commercial
products with information recipes. After completing the
food record, participants met with the dietician to review
all the information for record accuracy, completeness
and portion size of individual items. When needed, food
models were used.
Food Frequency Questionnaire (FFQ)
FFQ inquires about food habits of certain time period
and it is based on defined list of typical food items [26].
In comparison to other records FFQ comprises longer
time of dietary intake, imposes less burden on patients
and is quick and easy to complete. However the preci-
sion in quantifying intakes may be questioned. FFQ is
preferred method in large cross-sectional and cohort
studies in children.
For the purpose of our study FFQs were administered
by registered dieticians who interviewed children and their
parents in all centres. The questionnaire was modified in
order to get key information about food ingredients vital
for the development of obesity and metabolic syndrome
e.g. saturated fatty acids, carbohydrates and antioxidants
and on the other hand, these that protect organism from
metabolic syndrome development, such us unsaturated
fatty acids and antioxidants. Dieticians used food models
for an approximate estimation of the portion consumed
by the patient. The list contained over 300 products: typ-
ical dishes, raw materials, processed food, fluids and diet-
ary supplements. Participants were asked about frequency
of intake for different food during the last month in termsof day, week or month. Where available they had to pro-
vide recipes for consumed products. Parents were
supporting the minors in completing the record. The
FFQ was performed at the beginning (week 0) and the
end of study medication treatment (week 24).
Data of consumed food were calculated to 1 day
amount intake and recalculated into nutrients and
energy by Energia FFQ software by Andrzej MiegocW.
It offered a database of nutritional value of food and
products as well as option to add new food items and
recipes.
Dietetic intervention
All patients were encouraged to apply to their individu-
ally defined diet, which in combination with increased
physical activity, aimed at slow reduction of body weight
(approximately 0,5 kg per week) [27]. As calculated, this
can be achieved with daily energy deficit of about
500 kcal. The main criterion for efficacy of our dietary
intervention was the body weight loss by at least 5%.
Based on the data from dietary records (3 day food rec-
ord and FFQ) dieticians instructed patients about the ne-
cessary dietary modifications and habits they had to adhere.
Patients received the following dietary recommendations:
– low-calorie diet
– maximum 5% of total energy from simple
carbohydrates
– dietary glycemic index <50
– 30% of the total energy from lipids with proportion
of saturated/monounsaturated/polyunsaturated fatty
acids as 1:1:1
– adequate protein intake
The advised caloricity of the diet varied from 1500 to
1900kcal per day with respect to patient’s age, gender
and level of physical activity to achieve expected weight
reduction of 0,5 kg per week. Participants received ex-
amples of menus that matched necessary energy intake.
Patients were aware to measure their body weight every
week. In case of excessive weight gain the dietician
might suggest decreased calorie intake and/or increased
physical activity.
Physical activity assessment
To assess the level of physical activity and sedentary life-
style we used the modified International Physical Activity
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publically available surveillance system that was validated
on large cohorts in a number of studies [28]. Answers to
a set of questions assign the participant to a certain
physical activity level (low, moderate or high). The IPAQ
protocol is designed to be self-reported by a patient,
however in our study parents assisted children in its
completion.
Outcome measures
Primary outcome measure of the study is a number of pa-
tients in whom ALT level decreased by minimum 0,3
ULN (upper limit of normal) after the 6 months of treat-
ment with omega-3 when compared to the placebo group.
Secondary outcomes include the following parameters
compared between omega-3 and placebo group after 6
months of treatment:
▪ normalization of ALT activity at week 24
▪ decrease of ALT, AST, GGTP and other liver function
tests,
▪ normalization or improvement of liver steatosis on
ultrasound based on Saverymuttu scoring system [29],
▪ changes in the level of fasting glucose and insulin,
cholesterol and lipid profile,
▪ changes in insulin resistance markers as insulin,
HOMA-IR, adipokines,
▪ alterations in the basic hematology and biochemical
lab tests,
▪ difference in fat and lean body mass measurements
(using electric bioimpedance TANITAW Body
Composition Analyzer BC 418MA),
▪ caloric intake as well as intake of fats, fatty acids and
sucrose.
Other outcomes comprise of changes in anthropometric
measures of body weight (e.g. height, hip/waist circum-
ference, triceps, subscapular and abdominal skinfolds
thickness) as well as vital signs like heart rate and blood
pressure.
In selected subgroups of patients we will also examine
effect of treatment on:
▪ serum antioxidants e.g. glutathione, glutathione
peroxidase, tromboxane,
▪ cytokines e.g. TNF-α
▪ fatty acid composition of plasma phospholipids
[%wt/wt],
▪ bone mass density and fat content using dual x-ray
absorptiometry (DEXA) (Lunar Prodigy, General
Electric Healthcare, United States) - in a subgroup of
patients who were eligible for this investigation in 2
centers,
▪ liver imaging by MR and fat content on 1H-MRS - in
subgroups of patients who were eligible for these
investigations,▪ adipose tissue distribution on MRI - in a subgroup of
patients who were eligible for this investigation in
1 center.
Sample size
We decided to use decrease of ALT by 0.3 upper limit of
normal value as the primary endpoint of the study. It was
estimated that a sample size of 80 patients would be suffi-
cient to reveal a difference in the treatment effect of 30%
(45% in experimental group vs. 15% in control group) con-
sidering α = 0.05 and a power (β) of 80%. The number of
80 children accounted for approximately 20% withdrawals
or losses. The sample size was calculated with StatDirect
software version 2.7.9 (StatsDirect Ltd., England, UK).
Statistical analysis
Data will be presented as medians with quartile range.
The Mann–Whitney U test will be used for comparisons
of median values between groups. The calculations will
be performed with PASW Statistics 18 version 18.0.0,
Polar Engineering and ConsultingW.
For the categorical data analysis (for the primary end
point and selected secondary end points) data will be or-
ganized in contingency tables, tested for difference be-
tween observed and expected values and appropriate
tests will be applied to test the null hypothesis of no dif-
ference between the groups (chi-square or Fischer’s
exact test) with StatsDirect version 2.7.9 (StatsDirect
Ltd., England, UK). The differences will be regarded sig-
nificant at p<0.05. Statistical methods will be applied for
intention-to-treat and per protocol analysis.
Conduct of the trial
Study visits overview
The study will be divided into the selection period, treat-
ment period and the follow-up.
In the selection period patients were carefully screened
to confirm diagnosis of NAFLD and to identify any po-
tential exclusion criteria.
On the first visit at week 0 (M0) patients with NAFLD
undergo wide-range physical, anthropometric, laboratory
and imaging investigations. When eligible they are in-
cluded in the study, randomized and receive study drug
or placebo. At the same time patients are consulted by
dietician, report 3-day food record, FFQ and IPAQ. They
are instructed about their individual low-calorie diet and
how to keep increased level of physical activity.
During the treatment period next two visits are planned:
– M1 at 12 weeks after the inclusion,
– M2 at 24 weeks after the inclusion.
At visit M1 a routine physical examination along with
simplified laboratory tests and anthropometry are done.
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the physician and consult their diet with a dietician.
At visit M2 patients undergo physical examination,
comprehensive laboratory and imaging examinations.
Repeated food and physical activity questionnaires are
recorded. Patients stop taking the study drug however
the lifestyle recommendations are further maintained.
A follow-up visit (M3) is scheduled 6 months after
the end of therapy to check whether changes of body
weight, laboratory parameters of liver function and
imaging are sustained.
Blood tests measurements perform the local laborator-
ies, except for antioxidants, cytokines and fatty acids
profile that are sent to the central laboratory. Upper
limit of normal of ALT activity varies between the four
medical centers (40–45 U/L), therefore in the statistical
analysis we will calculate and use a percentage of the
ULN.
Each anthropometric parameter and vital sign was
measured twice and the mean value was taken into sta-
tistics. Systolic/diastolic blood pressure and heart rate
were measured by the automatic blood pressure device
(Dinamap XL, CritikonW, U.S.). Patients rested for 10
minutes in the supine position before measurement.
Arm circumference was set midway between the shoul-
der tip and the olecranon process. The same arm was
used throughout the study.
One experienced radiologist was performing abdom-
inal ultrasound at each centre and estimated the degree
of liver steatosis according to Saverymuttu scoring sys-
tem [29]. When applicable, liver biopsy was done and
assessed by two independent pathologists. At each
centre a registered dietician administered food records
and monitored adherence to the dietary regime.
At every visit any adverse events (AEs), that have oc-
curred since the last visit and changes in the concomi-
tant treatment were documented. For all investigations
the data were entered into electronic case report form
(eCRF) system and stored there anonymously.
The detailed schedule of the trial visits and investiga-
tions are summarized in Table 2.
Randomization
Eligible participants who fulfilled inclusion criteria were
randomized into the trial. Using computer statistical
software StatsDirect version 2.7.9 (StatsDirect Ltd.,
England, UK) the list of random treatment assignments
was generated. Randomization was made to two arms
(omega-3 or placebo), in blocks of four individuals,
stratified by centre. The use of centre stratification
guarantees balance and increases statistical accuracy.
Investigators sent randomizations requests by fax to
the central randomization center (CRC) responsible for
the process of randomization. In return they received arandom number that was subsequently allocated to the
choice of one of the products (numbered 100 or 101).
Treatment dispensing and assessment of compliance
All the study treatments were provided in a capsule
form. Identical appearance of capsules for both arms
(omega-3 and placebo) ensured the double blind study
design. Study drug were stored in plastic boxes
containing 200 capsules at room temperature. The
boxes were the same for the two treatments arms,
blinded by a manufacturer, marked with 3 digits:
“100” or “101” – for omega-3 or placebo.
Study treatment was dispensed by the investigator at
the inclusion visit M0. After the validation of patient’s
eligibility the investigator contacted with the CRC to de-
clare the inclusion of the patient and allocate his/her
therapeutic unit number. The kit number attributed by
CRC corresponded to the randomized treatment arm.
The box marked with respective kit number were given
to the patient.
At the visit M1 the treatment pack allocated at the
previous visit was retrieved from the patient and the
drug accountability of the remaining capsules was
performed.
At the final M2 study visit the kits allocated at visits
M0 and M1 were retrieved from the patient. The num-
ber of used and remaining capsules were documented to
estimate the compliance with the study drug. When the
study had been completed no new allocation of treat-
ment was made.Results
Patients recruitment for the trial started in 2008 and
ended in 2011. From a total of 86 screened participants
10 were found ineligible (11.6%). The most frequent rea-
son for ineligibility was ALT activity <1.3x ULN. A total
of 76 children with NAFLD met the inclusion criteria
and were randomly assigned to receive either the
omega-3 (n=38) or placebo (n=38).
The follow-up of the study is still ongoing. We are
currently finalizing data collection obtained after 24
weeks of treatment. The full statistical analysis of the
study results will be completed in the mid-2013.
Discussion
Marine omega-3 fatty acids are very promising diet-
ary supplements used in prevention and therapy of
cardiovascular, inflammatory, immunological, psycho-
logical and neurological disorders. They are safe pharma-
cological agents within the wide range of dose, what was
shown in several studies including pregnancy, newborns
and elderly and confirmed by the European Food Safety
Authority (EFSA) in 2012 [30].
Table 2 Investigation schedule
Procedure Inclusion Treatment period Follow-up
M0 M1 M2 M3
Week 0 Week 12 Week 24 Week 48
Written consent X
Medical history X X X X
Randomization X
Study drug dispensing X X
End of study drug treatment X
Compliance X X X
Adverse events monitoring X X X
Previous and concomitant treatment X X X X
Vital signs and physical examination X X X X
Anthropometry + TANITAW bioimpedance X X X X
Abdominal utrasound X X X
aLiver biopsy X
Dietary assessment:
- dietetic counseling X X X X
- 3 day food record X
- FFQ X X
Physical activity:
- general counselling X X X X
- IPAQ X X
Laboratory tests:
- hematology X X
- ALT,AST, GGTP, bilirubin, INR X X X X
- fasting glucose, insulin X X X X
- OGTT glucose, insulin 0-240mins X
- fasting lipids profile X X X
- adipokines, cytokines, antioxidants X X
- fatty acid composition of plasma phospholipids X X
aDEXA X X
aMRI - body fat distribution X X
a1H-MRS - liver fat content X X
aDone in selected patients.
Vital signs: mean BP, HR and temperature.
Anthropometry includes measurements of body weight and height, waist, hips and mid upper arm circumference (IOTF, WHO), triceps, abdominal and
subscapular skin fold thickness.
OGTT glucose and insulin measurements were performed in intervals every 30 minutes from 0 to 240 minutes.
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secondary to their anti-inflammatory, antithrombotic, an-
tiarrhythmic, hypolipidemic and vasodilatory properties
[16-19,31-38]. There is an evidence they could improve
lipid prolife by lowering triglycerides, decrease insulin re-
sistance and cytokine synthesis [19,34-38]. These effects
may be linked with the pathogenesis of NAFLD.
Already a number of studies showed efficacy of omega-
3 fatty acids in the metabolic syndrome-related condi-
tions [37-41]. Therefore omega-3 fatty acids may be
potentially promising medication in the treatment of
NAFLD.To our best knowledge, our study is one of the very
few double-blind, placebo-controlled randomized trials
testing efficacy of omega-3 in children with NAFLD. Pre-
viously Nobili et al. supplemented a group of 60 children
with either DHA or placebo for 6 months. The therapy
decreased liver steatosis on ultrasound, improved triglyc-
erides and insulin resistance markers, however no change
in ALT activity was observed [21]. Further pediatric trials
supporting or refuting use of omega-3 fatty in NAFLD
are needed.
The review of the literature of randomized trials suggests
that wide-range doses (0,8-13,7g per day) of omega-3 fatty
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optimal dose and proportion in the treatment of NAFLD
has not been agreed yet [20]. Moreover the evidence is lim-
ited in children. We used omega-3 formula containing EPA
and DHA, that should combine positive metabolic (mostly
EPA) and anti-inflammatory effects (DHA). The compos-
ition of the studied supplement consisted of pre-defined
DHA/EPA ratio (3:2). The chosen dose and content of
omega-3 in our study was decided on the basis of review of
the promising results from available open-label studies and
it is a compromise that should provide safety and efficacy
of therapy [42]. However, the study is testing only one dose
of omega-3 instead of multiple doses to determine the
dose–response relationship. Use of sunflower oil as a pla-
cebo/comparator may be justified because omega-6 are
commonly present in a regular diet and the given dose does
not influence their nutritional balance.
Weight-dependent dosing may be controversial, but it
has to be regarded that the participants are children aged
from 6 years to 19 years. The body mass might vary
largely in this cohort, therefore differentiation between
pediatric and adult doses can be explained. We subject-
ively set the weight margin at 40 kg and 60 kg for dosage
of omega-3 but there are also several studies in children
supplementing omega-3 for various indications in weight-
dependent manner (per range and per kg) [43,44].
6-month duration of treatment is frequently applied in
clinical trials with dietetic supplements like fish oil and
it is considered sufficient to achieve therapeutic results
and maintain satisfactory compliance [9,13,20].
The strength of our study is a well designed ran-
domization and data collection system, clearly defined diet-
ary counseling and a wide-range of parameters tested.
In most previous trials investigating pharmacological
treatment for NAFLD, dietetic surveillance was poorly
described.
Several methods for assessment of body composition
were used in our study (e.g. anthropometry, bioelectric
impedance, MRI and DEXA). Among them DEXA be-
comes the gold standard method giving accurate and non-
invasive measure of bone, fat distribution, and muscle
tissues during single procedure of total body scan. Data
obtained from all these techniques will be studied to esti-
mate the efficacy of treatment and compared between
each other to select the most reliable method reflecting
changes of body composition in our patients.
The limitation of our study is the definition of NAFLD
which is based on ultrasound and ALT (both criteria ful-
filled together). Still, this allows to enroll those who
present with significant steatosis (as indicated by ultra-
sound) and possibly inflammation (as indicated by ALT).
Liver biopsy is rarely used to select children with
NAFLD and for assessment of therapy as there are li-
mited indications for liver biopsy in children.To minimize possible bias we designed randomized,
double-blind trial. Study treatment and placebo have
identical appearance of capsules and packaging in plastic
pill boxes to ensure the double blind study design. Data
of the patients are entered and organized in the elec-
tronic case report form (e-CRF). The treatment allocation
to the patients is done using a centralized randomization.
Randomization is fixed, balanced and stratified according
to centre. Both e-CRF and randomization are carried by
the external company. Ultrasound was performed each
time by the same radiologist, histology of the liver was
assessed by two independent pathologists. Advanced lab
tests are sent and examined in the central laboratory.
As there is no efficient pharmacological treatment for
NAFLD, the positive result of this randomized trial will
place omega-3 fatty acids as a useful agent in the treat-
ment of NAFLD in children which can be safely applied
together with lifestyle modification. No or negative effect
of supplementation will add valuable evidence against its
use in NAFLD. Nevertheless, final findings are expected
to strongly contribute to the knowledge base and public
health guidelines regarding use of omega-3 fatty acids
in NAFLD, metabolic syndrome and obesity-related
diseases.
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